Autologous Hematopoietic Stem Cell Transplantation—10 Years of Data From a Developing Country

• DOI: 10.5966/sctm.2015-0015
• Publication Date: 2015-06-02T02:51:11Z
• Authors: Natasha Ali; Salman Naseem Adil; Mohammad Usman Sh...
• Keywords: Melphalan; Carmustine; Autologous stem-cell transplantation

Intensive chemotherapy followed by autologous stem cell transplantation is the treatment of choice for patients with hematological malignancies. The objective present study was to evaluate outcomes mainly lymphoma and multiple myeloma after transplant. pretransplant workup consisted complete blood count, an evaluation liver, kidney, lung, infectious profile, chest radiographs, a dental review. For lymphoma, all who achieved at least 25% reduction in disease salvage therapy were included study. Mobilization done cyclophosphamide, granulocyte colony-stimulating factor, 300 µg twice daily. conditioning regimens BEAM (carmustine, etoposide, cytarabine, melphalan) high-dose melphalan. A total 206 transplants performed from April 2004 December 2014. Of these, 137 allogeneic 69 autologous. receiving transplant, 49 male 20 female. patients, 26 underwent Hodgkin's 23 non-Hodgkin's 15 4 1 Ewing's sarcoma neuroblastoma, respectively. median age ± SD 34 13.1 years (range, 4-64). mean 4.7 × 10⁸ 1.7 mononuclear cells per kilogram infused. time white recovery 18.2 5.34 days. Transplant-related mortality occurred 10 patients. After follow-up period 104 months, overall survival rate 86%. High-dose chemotherapy, effective option malignancies, allowing further consolidation response.